Zacks Research Estimates Amarin's Q3 Earnings (NASDAQ:AMRN)

Amarin Corporation PLC (NASDAQ:AMRN - Free Report) - Investment analysts at Zacks Research lifted their Q3 2025 earnings per share (EPS) estimates for shares of Amarin in a note issued to investors on Wednesday, June 25th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of ($0.60) per share for the quarter, up from their previous forecast of ($0.74). The consensus estimate for Amarin's current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin's Q4 2025 earnings at ($1.01) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($1.59) EPS, Q1 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.67) EPS.

A number of other equities research analysts have also weighed in on the stock. Wall Street Zen upgraded shares of Amarin from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. The Goldman Sachs Group increased their target price on Amarin from $7.00 to $12.00 and gave the company a "sell" rating in a report on Wednesday.

Amarin Stock Down 1.2%

Amarin stock traded down $0.19 during trading on Friday, reaching $15.71. The stock had a trading volume of 112,529 shares, compared to its average volume of 81,128. Amarin has a 52-week low of $7.08 and a 52-week high of $17.18. The stock has a market cap of $325.35 million, a PE ratio of -4.32 and a beta of 0.71. The business has a 50 day moving average price of $11.79 and a 200 day moving average price of $10.69.

Amarin (NASDAQ:AMRN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. Amarin had a negative return on equity of 17.21% and a negative net margin of 41.07%.

Institutional Trading of Amarin

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AMRN. Banque Cantonale Vaudoise acquired a new stake in Amarin during the 1st quarter worth $25,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Amarin during the fourth quarter worth about $36,000. Kornitzer Capital Management Inc. KS lifted its holdings in shares of Amarin by 4.0% in the 1st quarter. Kornitzer Capital Management Inc. KS now owns 88,200 shares of the biopharmaceutical company's stock valued at $40,000 after purchasing an additional 3,400 shares during the last quarter. Generation Capital Management LLC acquired a new stake in shares of Amarin in the 4th quarter valued at about $50,000. Finally, Stonepine Capital Management LLC purchased a new position in Amarin during the 4th quarter worth approximately $55,000. Institutional investors and hedge funds own 22.25% of the company's stock.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.